<DOC>
	<DOCNO>NCT00132522</DOCNO>
	<brief_summary>This study look safety tolerability experimental biological drug EMD 273066 give low dose cyclophosphamide patient recur EpCAM positive ovarian , prostate , colorectal non-small cell lung cancer . EMD 273066 experimental biological drug may increase immune response certain cancer . Patients enrol group 3 , successive group receive high dose prior group adequately tolerate study medication .</brief_summary>
	<brief_title>EMD 273066 Patients With Recurrent EpCAM Positive Ovarian , Prostate , Colorectal Non-small Cell Lung Cancers When First Given Cyclophosphamide</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Recurrent nonsmall cell lung , colorectal , ovarian prostate cancer No two line prior chemotherapy Positive EpCAM expression Karnofsky Performance Status &gt; 70 % Adequate laboratory result Normal cardiac stress test Evidence brain metastasis Pregnant lactate female Significant infection Prior receipt EMD 273066 Unable interrupt antihypertensive medication 2 day prior cycle study medication administration Uncontrolled hypertension Previous diagnosis Addison 's disease Previous diagnosis autoimmune disease Organ transplant Insulindependent diabetes History acute pancreatitis Congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>EpCAM</keyword>
	<keyword>monoclonal-antibody</keyword>
	<keyword>target therapy</keyword>
	<keyword>colorectal</keyword>
	<keyword>prostate</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>ovarian</keyword>
	<keyword>solid tumor</keyword>
</DOC>